OBJECTIVES: The objective of this research is to characterize the EUnetHTA [European Network for Health Technology Assessment] members based on their influence/position in their respective national reimbursement process of pharmaceuticals/other technologies and their responsibility to produce HTAs within their national setting. METHODS: The organizations, in total counting 69, are rated according to their position and decision-making influence within the national reimbursement process. Categorizations will be: 1. responsible for the reimbursement decision; 2. adviser, scientific supplier in the reimbursement process; 3. not actively involved in the reimbursement process. In addition, the production of national HTAs – defined as an assessment of at least the relative effectiveness and safety of pharmaceuticals/other technologies - will be explored and rated as: 1. production of HTAs; 2. no production of HTAs. Primary source for information gathering will be the websites of the EUnetHTA member organizations. Two independent researchers will extract the data, a member check will be conducted subsequent. Inclusion criteria for the information are: English language, not older than 2013, publicly available. If no information is available on the respective websites, general overviews about countries are used for additional information research and validation. RESULTS: Preliminary results:  1. 13 organizations (19%), 2. 21 organizations (30%), 3. 29 organizations (42%). 6 organizations did not have available information on their homepage. Validation will be conducted through general overviews of the countries. Information regarding the HTA production of the 69 organizations is expected soon.   CONCLUSIONS: The preliminary results present that around 50% of the EUnetHTA members are actively involved in the reimbursement process as responsible body for the decision-making or as adviser. Further research is needed to identify the influence of EUnetHTA members and their respective role in the national setting on EUnetHTA work.